Cargando…

Dopamine modulates individual differences in avoidance behavior: A pharmacological, immunohistochemical, neurochemical and volumetric investigation

Avoidance behavior is a hallmark in pathological anxiety disorders and results in impairment of daily activities. Individual differences in avoidance responses are critical in determining vulnerability or resistance to anxiety disorders. Dopaminergic activation is implicated in the processing of avo...

Descripción completa

Detalles Bibliográficos
Autores principales: Antunes, Geiza Fernanda, Gouveia, Flavia Venetucci, Rezende, Fabiana Strambio, Seno, Midiã Dias de Jesus, de Carvalho, Milene Cristina, de Oliveira, Caroline Cruz, dos Santos, Lennon Cardoso Tosati, de Castro, Marina Correia, Kuroki, Mayra Akemi, Teixeira, Manoel Jacobsen, Otoch, José Pinhata, Brandao, Marcus Lira, Fonoff, Erich Talamoni, Martinez, Raquel Chacon Ruiz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231994/
https://www.ncbi.nlm.nih.gov/pubmed/32435668
http://dx.doi.org/10.1016/j.ynstr.2020.100219
_version_ 1783535290250428416
author Antunes, Geiza Fernanda
Gouveia, Flavia Venetucci
Rezende, Fabiana Strambio
Seno, Midiã Dias de Jesus
de Carvalho, Milene Cristina
de Oliveira, Caroline Cruz
dos Santos, Lennon Cardoso Tosati
de Castro, Marina Correia
Kuroki, Mayra Akemi
Teixeira, Manoel Jacobsen
Otoch, José Pinhata
Brandao, Marcus Lira
Fonoff, Erich Talamoni
Martinez, Raquel Chacon Ruiz
author_facet Antunes, Geiza Fernanda
Gouveia, Flavia Venetucci
Rezende, Fabiana Strambio
Seno, Midiã Dias de Jesus
de Carvalho, Milene Cristina
de Oliveira, Caroline Cruz
dos Santos, Lennon Cardoso Tosati
de Castro, Marina Correia
Kuroki, Mayra Akemi
Teixeira, Manoel Jacobsen
Otoch, José Pinhata
Brandao, Marcus Lira
Fonoff, Erich Talamoni
Martinez, Raquel Chacon Ruiz
author_sort Antunes, Geiza Fernanda
collection PubMed
description Avoidance behavior is a hallmark in pathological anxiety disorders and results in impairment of daily activities. Individual differences in avoidance responses are critical in determining vulnerability or resistance to anxiety disorders. Dopaminergic activation is implicated in the processing of avoidance responses; however, the mechanisms underlying these responses are unknown. In this sense, we used a preclinical model of avoidance behavior to investigate the possibility of an intrinsic differential dopaminergic pattern between good and poor performers. The specific goal was to assess the participation of dopamine (DA) through pharmacological manipulation, and we further evaluated the effects of systemic injections of the dopaminergic receptor type 1 (D1 antagonist - SCH23390) and dopaminergic receptor type 2 (D2 antagonist - sulpiride) antagonists in the good performers. Additionally, we evaluated the effects of intra-amygdala microinjection of a D1 antagonist (SCH23390) and a D2 antagonist (sulpiride) in good performers as well as intra-amygdala microinjection of a D1 agonist (SKF38393) and D2 agonist (quinpirole) in poor performers. Furthermore, we quantified the contents of dopamine and metabolites (3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA)) in the amygdala, evaluated the basal levels of tyrosine hydroxylase expression (catecholamine synthesis enzyme) and measured the volume of the substantia nigra, ventral tegmental area and locus coeruleus. Our results showed that it could be possible to convert animals from good to poor performers, and vice versa, by intra-amygdala (basolateral and central nucleus) injections of D1 receptor antagonists in good performers or D2 receptor agonists in poor performers. Additionally, the good performers had lower levels of DOPAC and HVA in the amygdala, an increase in the total volume of the amygdala (AMG), substantia nigra (SN), ventral tegmental area (VTA) and locus coeruleus (LC), and an increase in the number of tyrosine hydroxylase-positive cells in SN, VTA and LC, which positively correlates with the avoidance behavior. Taken together, our data show evidence for a dopaminergic signature of avoidance performers, emphasizing the role of distinct dopaminergic receptors in individual differences in avoidance behavior based on pharmacological, immunohistochemical, neurochemical and volumetric analyses. Our findings provide a better understanding of the role of the dopaminergic system in the execution of avoidance behavior.
format Online
Article
Text
id pubmed-7231994
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-72319942020-05-20 Dopamine modulates individual differences in avoidance behavior: A pharmacological, immunohistochemical, neurochemical and volumetric investigation Antunes, Geiza Fernanda Gouveia, Flavia Venetucci Rezende, Fabiana Strambio Seno, Midiã Dias de Jesus de Carvalho, Milene Cristina de Oliveira, Caroline Cruz dos Santos, Lennon Cardoso Tosati de Castro, Marina Correia Kuroki, Mayra Akemi Teixeira, Manoel Jacobsen Otoch, José Pinhata Brandao, Marcus Lira Fonoff, Erich Talamoni Martinez, Raquel Chacon Ruiz Neurobiol Stress Original Research Article Avoidance behavior is a hallmark in pathological anxiety disorders and results in impairment of daily activities. Individual differences in avoidance responses are critical in determining vulnerability or resistance to anxiety disorders. Dopaminergic activation is implicated in the processing of avoidance responses; however, the mechanisms underlying these responses are unknown. In this sense, we used a preclinical model of avoidance behavior to investigate the possibility of an intrinsic differential dopaminergic pattern between good and poor performers. The specific goal was to assess the participation of dopamine (DA) through pharmacological manipulation, and we further evaluated the effects of systemic injections of the dopaminergic receptor type 1 (D1 antagonist - SCH23390) and dopaminergic receptor type 2 (D2 antagonist - sulpiride) antagonists in the good performers. Additionally, we evaluated the effects of intra-amygdala microinjection of a D1 antagonist (SCH23390) and a D2 antagonist (sulpiride) in good performers as well as intra-amygdala microinjection of a D1 agonist (SKF38393) and D2 agonist (quinpirole) in poor performers. Furthermore, we quantified the contents of dopamine and metabolites (3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA)) in the amygdala, evaluated the basal levels of tyrosine hydroxylase expression (catecholamine synthesis enzyme) and measured the volume of the substantia nigra, ventral tegmental area and locus coeruleus. Our results showed that it could be possible to convert animals from good to poor performers, and vice versa, by intra-amygdala (basolateral and central nucleus) injections of D1 receptor antagonists in good performers or D2 receptor agonists in poor performers. Additionally, the good performers had lower levels of DOPAC and HVA in the amygdala, an increase in the total volume of the amygdala (AMG), substantia nigra (SN), ventral tegmental area (VTA) and locus coeruleus (LC), and an increase in the number of tyrosine hydroxylase-positive cells in SN, VTA and LC, which positively correlates with the avoidance behavior. Taken together, our data show evidence for a dopaminergic signature of avoidance performers, emphasizing the role of distinct dopaminergic receptors in individual differences in avoidance behavior based on pharmacological, immunohistochemical, neurochemical and volumetric analyses. Our findings provide a better understanding of the role of the dopaminergic system in the execution of avoidance behavior. Elsevier 2020-04-08 /pmc/articles/PMC7231994/ /pubmed/32435668 http://dx.doi.org/10.1016/j.ynstr.2020.100219 Text en © 2020 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Research Article
Antunes, Geiza Fernanda
Gouveia, Flavia Venetucci
Rezende, Fabiana Strambio
Seno, Midiã Dias de Jesus
de Carvalho, Milene Cristina
de Oliveira, Caroline Cruz
dos Santos, Lennon Cardoso Tosati
de Castro, Marina Correia
Kuroki, Mayra Akemi
Teixeira, Manoel Jacobsen
Otoch, José Pinhata
Brandao, Marcus Lira
Fonoff, Erich Talamoni
Martinez, Raquel Chacon Ruiz
Dopamine modulates individual differences in avoidance behavior: A pharmacological, immunohistochemical, neurochemical and volumetric investigation
title Dopamine modulates individual differences in avoidance behavior: A pharmacological, immunohistochemical, neurochemical and volumetric investigation
title_full Dopamine modulates individual differences in avoidance behavior: A pharmacological, immunohistochemical, neurochemical and volumetric investigation
title_fullStr Dopamine modulates individual differences in avoidance behavior: A pharmacological, immunohistochemical, neurochemical and volumetric investigation
title_full_unstemmed Dopamine modulates individual differences in avoidance behavior: A pharmacological, immunohistochemical, neurochemical and volumetric investigation
title_short Dopamine modulates individual differences in avoidance behavior: A pharmacological, immunohistochemical, neurochemical and volumetric investigation
title_sort dopamine modulates individual differences in avoidance behavior: a pharmacological, immunohistochemical, neurochemical and volumetric investigation
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7231994/
https://www.ncbi.nlm.nih.gov/pubmed/32435668
http://dx.doi.org/10.1016/j.ynstr.2020.100219
work_keys_str_mv AT antunesgeizafernanda dopaminemodulatesindividualdifferencesinavoidancebehaviorapharmacologicalimmunohistochemicalneurochemicalandvolumetricinvestigation
AT gouveiaflaviavenetucci dopaminemodulatesindividualdifferencesinavoidancebehaviorapharmacologicalimmunohistochemicalneurochemicalandvolumetricinvestigation
AT rezendefabianastrambio dopaminemodulatesindividualdifferencesinavoidancebehaviorapharmacologicalimmunohistochemicalneurochemicalandvolumetricinvestigation
AT senomidiadiasdejesus dopaminemodulatesindividualdifferencesinavoidancebehaviorapharmacologicalimmunohistochemicalneurochemicalandvolumetricinvestigation
AT decarvalhomilenecristina dopaminemodulatesindividualdifferencesinavoidancebehaviorapharmacologicalimmunohistochemicalneurochemicalandvolumetricinvestigation
AT deoliveiracarolinecruz dopaminemodulatesindividualdifferencesinavoidancebehaviorapharmacologicalimmunohistochemicalneurochemicalandvolumetricinvestigation
AT dossantoslennoncardosotosati dopaminemodulatesindividualdifferencesinavoidancebehaviorapharmacologicalimmunohistochemicalneurochemicalandvolumetricinvestigation
AT decastromarinacorreia dopaminemodulatesindividualdifferencesinavoidancebehaviorapharmacologicalimmunohistochemicalneurochemicalandvolumetricinvestigation
AT kurokimayraakemi dopaminemodulatesindividualdifferencesinavoidancebehaviorapharmacologicalimmunohistochemicalneurochemicalandvolumetricinvestigation
AT teixeiramanoeljacobsen dopaminemodulatesindividualdifferencesinavoidancebehaviorapharmacologicalimmunohistochemicalneurochemicalandvolumetricinvestigation
AT otochjosepinhata dopaminemodulatesindividualdifferencesinavoidancebehaviorapharmacologicalimmunohistochemicalneurochemicalandvolumetricinvestigation
AT brandaomarcuslira dopaminemodulatesindividualdifferencesinavoidancebehaviorapharmacologicalimmunohistochemicalneurochemicalandvolumetricinvestigation
AT fonofferichtalamoni dopaminemodulatesindividualdifferencesinavoidancebehaviorapharmacologicalimmunohistochemicalneurochemicalandvolumetricinvestigation
AT martinezraquelchaconruiz dopaminemodulatesindividualdifferencesinavoidancebehaviorapharmacologicalimmunohistochemicalneurochemicalandvolumetricinvestigation